SEARCH

SEARCH BY CITATION

References

  • 1
    Stieber P, Aronsson AC, Bialk P et al. Tumor markers in lung cancer: EGTM recommendations. Anticancer Res 1999; 19: 28179.
  • 2
    Alaiya AA, Franzen B, Auer G, Linder S. Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. Electrophoresis 2000; 21: 12107.
  • 3
    Yang F, Xiao ZQ, Zhang XZ et al. Identification of tumor antigens in human lung squamous cell carcinoma by serological proteome analysis. J Proteome Res 2007; 6 (2): 7518.
  • 4
    Katayama M, Nakano H, Ishiuchi A et al. Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry. Surg Today 2006; 36: 108593.
  • 5
    Fujita Y, Nakanishi T, Hiramatsu M et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 2006; 12 (21): 641520.
  • 6
    Nakanishi T, Takeuchi T, Ueda K, Murao H, Shimizu A. Detection of eight antibodies in cancer patients’ sera against proteins derived from the adenocarcinoma A549 cell line using proteomics-based analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 838: 1520.
  • 7
    Okado-Matsumoto A, Matsumoto A, Fujii J, Taniguchi N. Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. J Biochem 2000; 127: 493501.
  • 8
    Chen G, Gharib TG, Huang CC et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002; 8: 2298305.
  • 9
    Montgomerie JZ, Gracy RW, Holshuh HJ, Keyser AJ, Bennett CJ, Schick DG. The 28K protein in urinary bladder, squamous metaplasia and urine is triosephosphate isomerase. Clin Biochem 1997; 30: 6138.
  • 10
    Ishiguro T, Nakajima M, Naito M, Muto T, Tsuruo T. Identification of genes differentially expressed in B16 murine melanoma sublines with different metastatic potentials. Cancer Res 1996; 56 (4): 8759.
  • 11
    Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 2003; 28: 3240.
  • 12
    Chen JW, Dodia C, Feinstein ST, Jain MK, Fisher AB. 1-Cys Peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. J Biol Chem 2000; 275: 284217.
  • 13
    Manevich Y, Sweitzer T, Pak JH, Feinstein SI, Muzykantov V, Fisher AB. 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proc Natl Acad Sci USA 2002; 99: 11599604.
  • 14
    Wang Y, Manevich Y, Feinstein SI, Fisher AB. Adenovirus-mediated transfer of the 1-cys peroxiredoxin gene to mouse lung protects against hyperoxic injury. Am J Physiol Lung Cell Mol Physiol 2004; 286: L118893.
  • 15
    Kinnula VL, Lehtonen S, Sormunen R et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 2002; 196: 31623.
  • 16
    Lehtonen ST, Svensk AM, Soini Y et al. Peroxiredoxins,a novel protein family in lung cancer. Int J Cancer 2004; 111: 51421.
  • 17
    Karasawa R, Ozaki S, Nishioka K, Kato T. Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases. Microbiol Immunol 2005; 49: 5765.
  • 18
    Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006; 1: 5139.
  • 19
    Chen Y, Zhang H, Xu AJ et al. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer 2006; 54: 95102.
  • 20
    Sheu CC, Yu YP, Tsai JR et al. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non small cell lung cancer. Int J Cancer 2006; 119 (6): 141926.
  • 21
    Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006; 260: 42934.
  • 22
    Ameglio F, Abbolito MR, Giannarelli D et al. Detection of Helicobacter pylori carriers by discriminate analysis of urea and pH levels in gastric juices. J Clin Pathol 1991; 44: 689697.
  • 23
    Merucci P, Taggi F, Marolla A et al. Discriminant analysis of Hodgkin’s lymphomas by age and serum proteins. Eur J Cancer Clin Oncol 1984; 20: 12437.
  • 24
    Shinozaki T, Chigira MK. Mutivariate analysis of serum tumor markers for diagnosis of skeletal metastases. Cancer 1992; 69: 10812.
  • 25
    Ameglio F, Giannarelli D, Cordiali-Fei P et al. Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and non-specific serum markers. Am J Clin Pathol 1994; 101: 71925.